
## Ivan Richter Vogelius

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6643343/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Radiation-Induced Toxicity Risks in Photon Versus Proton Therapy for Synchronous Bilateral Breast Cancer. International Journal of Particle Therapy, 2022, 8, 1-13.	1.8	0
2	RootPainter3D: Interactiveâ€machineâ€learning enables rapid and accurate contouring for radiotherapy. Medical Physics, 2022, 49, 461-473.	3.0	8
3	Proton vs photon radiation therapy for glioblastoma: Maximizing information from trial. Neuro-Oncology, 2022, 24, 849-850.	1.2	3
4	Robust extraction of biological information from diffusion-weighted magnetic resonance imaging during radiotherapy using semi-automatic delineation. Physics and Imaging in Radiation Oncology, 2022, 21, 146-152.	2.9	4
5	Patient-reported outcome during radiotherapy for head and neck cancer: the use of different PRO questionnaires. European Archives of Oto-Rhino-Laryngology, 2022, 279, 4199-4206.	1.6	5
6	Gating has a negligible impact on dose delivered in MRI-guided online adaptive radiotherapy of prostate cancer. Radiotherapy and Oncology, 2022, 170, 205-212.	0.6	17
7	Early non-cancer mortality risk prediction after curative-intent radiotherapy or chemoradiotherapy for head and neck squamous cell carcinoma. Radiotherapy and Oncology, 2022, , .	0.6	1
8	Multi-parametric PET/MRI for enhanced tumor characterization of patients with cervical cancer. European Journal of Hybrid Imaging, 2022, 6, 7.	1.5	3
9	Primary Hypothyroidism in Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review. International Journal of Radiation Oncology Biology Physics, 2021, , .	0.8	12
10	Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database. British Journal of Cancer, 2021, 125, 458-464.	6.4	4
11	Using Biometric Sensor Data to Monitor Cancer Patients During Radiotherapy: Protocol for the OncoWatch Feasibility Study. JMIR Research Protocols, 2021, 10, e26096.	1.0	5
12	Hematological toxicity in patients with solid malignant tumors treated with radiation – Temporal analysis, dose response and impact on survival. Radiotherapy and Oncology, 2021, 158, 175-183.	0.6	17
13	FDG-PET/CT identified distant metastases and synchronous cancer in squamous cell carcinoma of the head and neck: the impact of smoking and P16-s. European Archives of Oto-Rhino-Laryngology, 2021, , 1.	1.6	0
14	Intratumor heterogeneity is biomarker specific and challenges the association with heterogeneity in multimodal functional imaging in head and neck squamous cell carcinoma. European Journal of Radiology, 2021, 139, 109668.	2.6	4
15	A randomized phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma. Acta Oncológica, 2021, 60, 948-953.	1.8	2
16	A framework for voxelâ€based assessment of biological effect after proton radiotherapy in pediatric brain cancer patients using multiâ€modal imaging. Medical Physics, 2021, 48, 4110-4121.	3.0	11
17	Toward PET/MRI as one-stop shop for radiotherapy planning in cervical cancer patients. Acta Oncológica, 2021, 60, 1045-1053.	1.8	15
18	Distant metastases in squamous cell carcinoma of the pharynx and larynx: a population-based DAHANCA study. Acta Oncológica, 2021, 60, 1472-1480.	1.8	3

#	Article	IF	CITATIONS
19	Outcome-based multiobjective optimization of lymphoma radiation therapy plans. British Journal of Radiology, 2021, 94, 20210303.	2.2	6
20	Radiation Dose Escalation for Early Prostate Cancer: Reigniting the FLAME?. Journal of Clinical Oncology, 2021, 39, 3085-3086.	1.6	4
21	Robustness and Generalizability of Deep Learning Synthetic Computed Tomography for Positron Emission Tomography/Magnetic Resonance Imaging–Based Radiation Therapy Planning of Patients With Head and Neck Cancer. Advances in Radiation Oncology, 2021, 6, 100762.	1.2	7
22	Novel technologies in radiotherapy in the Nordic countries - report from the NACP2020/21 conference. Acta OncolÃ <sup>3</sup> gica, 2021, 60, 1383-1385.	1.8	1
23	FDC-PET/CT in the surveillance of head and neck cancer following radiotherapy. European Archives of Oto-Rhino-Laryngology, 2020, 277, 539-547.	1.6	16
24	High nodal FDG uptake increases risk of distant metastasis in patients with oropharyngeal squamous cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1039-1045.	6.4	2
25	Heterogeneity in tumours: Validating the use of radiomic features on 18F-FDG PET/CT scans of lung cancer patients as a prognostic tool. Radiotherapy and Oncology, 2020, 144, 72-78.	0.6	35
26	Multiple Testing, Cut-Point Optimization, and Signs of Publication Bias in Prognostic FDG–PET Imaging Studies of Head and Neck and Lung Cancer: A Review and Meta-Analysis. Diagnostics, 2020, 10, 1030.	2.6	2
27	Outcome in patients with isolated regional recurrence after primary radiotherapy for head and neck cancer. Head and Neck, 2020, 42, 3161-3170.	2.0	7
28	Feasibility of Multiparametric Positron Emission Tomography/Magnetic Resonance Imaging as a One-Stop Shop for Radiation Therapy Planning for Patients with Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1329-1338.	0.8	14
29	In Reply to Berk and Alfonso. International Journal of Radiation Oncology Biology Physics, 2020, 108, 834-835.	0.8	1
30	Intrafractional fiducial marker position variations in stereotactic liver radiotherapy during voluntary deep inspiration breath-hold. British Journal of Radiology, 2020, 93, 20200859.	2.2	16
31	Does multiparametric imaging with 18F-FDG-PET/MRI capture spatial variation in immunohistochemical cancer biomarkers in head and neck squamous cell carcinoma?. British Journal of Cancer, 2020, 123, 46-53.	6.4	13
32	Deep learning for identification of critical regions associated with toxicities after liver stereotactic body radiation therapy. Medical Physics, 2020, 47, 3721-3731.	3.0	22
33	ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood, 2020, 135, 1829-1832.	1.4	78
34	Analysis of early respiratory-related mortality after radiation therapy of non-small-cell lung cancer: feasibility of automatic data extraction for dose–response studies. Acta Oncológica, 2020, 59, 628-635.	1.8	5
35	Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study. Acta Oncológica, 2020, 59, 879-887.	1.8	8
36	Involved node radiation therapy in the combined modality treatment for early-stage Hodgkin lymphoma: Analysis of relapse location and long-term outcome. Radiotherapy and Oncology, 2020, 150, 236-244.	0.6	5

IVAN RICHTER VOGELIUS

#	Article	IF	CITATIONS
37	Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 107, 299-304.	0.8	37
38	Systematic use of patient reported outcome during radiotherapy for head and neck cancer: study protocol for the national DAHANCA 38 trial. Acta Oncológica, 2020, 59, 603-607.	1.8	7
39	Radiation dose-painting with protons vs. photons for head-and-neck cancer. Acta Oncológica, 2020, 59, 525-533.	1.8	11
40	Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients – initial observations. PLoS ONE, 2020, 15, e0231884.	2.5	11
41	Harnessing data science to advance radiation oncology. Molecular Oncology, 2020, 14, 1514-1528.	4.6	16
42	Title is missing!. , 2020, 15, e0231884.		0
43	Title is missing!. , 2020, 15, e0231884.		Ο
44	Title is missing!. , 2020, 15, e0231884.		0
45	Title is missing!. , 2020, 15, e0231884.		Ο
46	Dual-energy material decomposition for cone-beam computed tomography in image-guided radiotherapy. Acta Oncológica, 2019, 58, 1483-1488.	1.8	8
47	An investigative expansion of a competing risk model for first failure site in locally advanced non-small cell lung cancer. Acta Oncológica, 2019, 58, 1386-1392.	1.8	6
48	Lymphocyte Count Kinetics, Factors Associated with the End-of-Radiation-Therapy Lymphocyte Count, and Risk of Infection in Patients with Solid Malignant Tumors Treated with Curative-Intent Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 105, 812-823.	0.8	26
49	Comparing the patients' subjective experiences of acute side effects during radiotherapy for head and neck cancer with four different patient-reported outcomes questionnaires. Acta Oncológica, 2019, 58, 603-609.	1.8	22
50	Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients. British Journal of Cancer, 2019, 121, 125-130.	6.4	9
51	Inverse radiotherapy planning based on bioeffect modelling for locally advanced left-sided breast cancer. Radiotherapy and Oncology, 2019, 136, 9-14.	0.6	4
52	Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. British Journal of Cancer, 2019, 120, 1003-1006.	6.4	109
53	On the relation between improved loco-regional control and disease-free survival in head-and-neck cancer. Acta Oncológica, 2019, 58, 390-392.	1.8	1
54	Patterns of treatment failure in patients undergoing adjuvant or definitive radiotherapy for vulvar cancer. International Journal of Gynecological Cancer, 2019, 29, 857-862.	2.5	2

#	Article	IF	CITATIONS
55	Incorporating NTCP into Randomized Trials of Proton Versus Photon Therapy. International Journal of Particle Therapy, 2019, 5, 24-32.	1.8	2
56	Origin of Locoregional Recurrences After Definitive Intensity-modulated Radiation Therapy (IMRT) for Laryngeal Cancer Determined Based on Follow-up PET/CT Imaging. Cureus, 2019, 11, e3856.	0.5	3
57	Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-analysis of Randomized Trials. International Journal of Radiation Oncology Biology Physics, 2018, 100, 858-865.	0.8	62
58	A Competing Risk Model of First Failure Site after Definitive Chemoradiation Therapy for Locally Advanced Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 559-567.	1.1	16
59	Individualized estimates of overall survival in radiation therapy plan optimization — A concept study. Medical Physics, 2018, 45, 5332-5342.	3.0	6
60	Comparison of EORTC QLQ-C30 and PRO-CTCAEâ,,¢ Questionnaires on Six Symptom Items. Journal of Pain and Symptom Management, 2018, 56, 421-429.	1.2	11
61	Retrospective estimation of heart and lung doses in pediatric patients treated with spinal irradiation. Radiotherapy and Oncology, 2018, 128, 209-213.	0.6	3
62	SP-0556: Outcome prediction models – training and validation. Radiotherapy and Oncology, 2018, 127, S293-S294.	0.6	0
63	An Extended Hypofractionated Palliative Radiotherapy Regimen for Head and Neck Carcinomas. Frontiers in Oncology, 2018, 8, 206.	2.8	12
64	A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients. Oral Oncology, 2018, 81, 52-60.	1.5	8
65	Repeatability of FDG PET/CT metrics assessed in free breathing and deep inspiration breath hold in lung cancer patients. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 127-136.	1.0	2
66	A modeling study of functional magnetic resonance imaging to individualize target definition of seminal vesicles for external beam radiotherapy. Acta Oncológica, 2017, 56, 799-805.	1.8	3
67	Joint Estimation of Cardiac Toxicity and Recurrence Risks After Comprehensive Nodal Photon Versus Proton Therapy for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 97, 754-761.	0.8	46
68	A failure-type specific risk prediction tool for selection of head-and-neck cancer patients for experimental treatments. Oral Oncology, 2017, 74, 77-82.	1.5	10
69	Immunohistochemical and molecular imaging biomarker signature for the prediction of failure site after chemoradiation for head and neck squamous cell carcinoma. Acta Oncológica, 2017, 56, 1562-1570.	1.8	9
70	Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and/or deep inspiration breath hold. Radiotherapy and Oncology, 2017, 125, 41-47.	0.6	46
71	Survival and failure types after radiation therapy of vulvar cancer. Clinical and Translational Radiation Oncology, 2017, 5, 20-27.	1.7	4
72	Modeling tumor control probability for spatially inhomogeneous risk of failure based on clinical outcome data. Zeitschrift Fur Medizinische Physik, 2017, 27, 285-299.	1.5	5

IVAN RICHTER VOGELIUS

#	Article	IF	CITATIONS
73	Feasibility of Multiparametric Imaging with PET/MR in Head and Neck Squamous Cell Carcinoma. Journal of Nuclear Medicine, 2017, 58, 69-74.	5.0	44
74	Testosterone deficiency in testicular cancer survivors – a systematic review and metaâ€analysis. Andrology, 2016, 4, 382-388.	3.5	50
75	Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer. Radiotherapy and Oncology, 2016, 120, 76-80.	0.6	55
76	Prognostic Value of 18-Fluorodeoxyglucose in Independent Training and Validation Sets of Patients With HNSCC Largely Explained by Association With Tumor Volume. International Journal of Radiation Oncology Biology Physics, 2016, 94, 921.	0.8	0
77	Patterns of Failure and Origin of Recurrence on Positron Emission Tomography/Computed Tomography for Laryngeal Cancer Patients Treated With Definitive Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, S221.	0.8	0
78	Early lesion-specific 18F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer. Radiotherapy and Oncology, 2016, 118, 460-464.	0.6	11
79	Stereotactic radiosurgery versus decompressive surgery followed by postoperative radiotherapy for metastatic spinal cord compression (STEREOCORD): Study protocol of a randomized non-inferiority trial. Journal of Radiosurgery and SBRT, 2016, 4, S1-S9.	0.2	5
80	Prognostic value of 18F-fludeoxyglucose uptake in 287 patients with head and neck squamous cell carcinoma. Head and Neck, 2015, 37, 1274-1281.	2.0	18
81	Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematology,the, 2015, 2, e492-e502.	4.6	123
82	Reproducibility of <sup>18</sup> F-FDG PET uptake measurements in head and neck squamous cell carcinoma on both PET/CT and PET/MR. British Journal of Radiology, 2015, 88, 20140655.	2.2	31
83	A new method to estimate doses to the normal tissues after past extended and involved field radiotherapy for Hodgkin lymphoma. Radiotherapy and Oncology, 2015, 114, 206-211.	0.6	11
84	Minimizing Late Effects for Patients With Mediastinal Hodgkin Lymphoma: Deep Inspiration Breath-Hold, IMRT, or Both?. International Journal of Radiation Oncology Biology Physics, 2015, 92, 169-174.	0.8	109
85	Spatio-temporal stability of pre-treatment 18F-Fludeoxyglucose uptake in head and neck squamous cell carcinomas sufficient for dose painting. Acta Oncológica, 2015, 54, 1416-1422.	1.8	14
86	Immunohistochemical biomarkers and FDG uptake on PET/CT in head and neck squamous cell carcinoma. Acta Oncológica, 2015, 54, 1408-1415.	1.8	26
87	Dose-response of acute urinary toxicity of long-course preoperative chemoradiotherapy for rectal cancer. Acta OncolÃ <sup>3</sup> gica, 2015, 54, 179-186.	1.8	25
88	A DICOM based radiotherapy plan database for research collaboration and reporting. Journal of Physics: Conference Series, 2014, 489, 012100.	0.4	18
89	Prescribing and evaluating target dose in dose-painting treatment plans. Acta Oncológica, 2014, 53, 1251-1256.	1.8	9
90	Optimizing the radiation therapy dose prescription for pediatric medulloblastoma: Minimizing the life years lost attributable to failure to control the disease and late complication risk. Acta OncolA <sup>3</sup> gica, 2014, 53, 462-470.	1.8	18

#	Article	IF	CITATIONS
91	Comment on: "Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited‣tage Diffuse Large Bâ€Cell Lymphoma of the Bone (the IELSGâ€14 Study)― Oncologist, 2014 1289-1289.	, 193,.7	1
92	Towards individualized dose constraints: Adjusting the QUANTEC radiation pneumonitis model for clinical risk factors. Acta OncolÃ <sup>3</sup> gica, 2014, 53, 605-612.	1.8	61
93	Interactive Decision-Support Tool for Risk-Based Radiation Therapy Plan Comparison for Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2014, 88, 433-445.	0.8	34
94	Hippocampal sparing radiotherapy for pediatric medulloblastoma: impact of treatment margins and treatment technique. Neuro-Oncology, 2014, 16, 594-602.	1.2	36
95	Doses to head and neck normal tissues for early stage Hodgkin lymphoma after involved node radiotherapy. Radiotherapy and Oncology, 2014, 110, 441-447.	0.6	18
96	The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma. Pediatric Blood and Cancer, 2014, 61, 717-722.	1.5	44
97	Hypofractionated Radiation Therapy for Prostate Cancer: More Food for Thought From Recent Trial. Journal of Clinical Oncology, 2014, 32, 1852-1853.	1.6	3
98	Temporal Stability and Reproducibility of FDG-PET–Based Dose Painting Targets in Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S514-S515.	0.8	0
99	Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. Radiotherapy and Oncology, 2014, 111, 360-365.	0.6	102
100	Long-Term Results of a Randomized Trial in Locally Advanced Rectal Cancer: No Benefit From Adding a Brachytherapy Boost. International Journal of Radiation Oncology Biology Physics, 2014, 90, 110-118.	0.8	46
101	Doses to Carotid Arteries After Modern Radiation Therapy for Hodgkin Lymphoma: Is Stroke Still a Late Effect of Treatment?. International Journal of Radiation Oncology Biology Physics, 2013, 87, 297-303.	0.8	27
102	Modern Hypofractionation Schedules for Tangential Whole Breast Irradiation Decrease the Fraction Size-corrected Dose to the Heart. Clinical Oncology, 2013, 25, 147-152.	1.4	57
103	Meta-analysis of the Alpha/Beta Ratio for Prostate Cancer in the Presence of an Overall Time Factor: Bad News, Good News, or No News?. International Journal of Radiation Oncology Biology Physics, 2013, 85, 89-94.	0.8	179
104	Radiation Dose-Response Model for Locally Advanced Rectal Cancer After Preoperative Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 85, 74-80.	0.8	219
105	Modeling Freedom From Progression for Standard-Risk Medulloblastoma: A Mathematical Tumor Control Model With Multiple Modes of Failure. International Journal of Radiation Oncology Biology Physics, 2013, 87, 422-429.	0.8	5
106	In Reply to Arcangeli et al. International Journal of Radiation Oncology Biology Physics, 2013, 85, 898-899.	0.8	0
107	Estimated Doses and Late Effect Risks After Involved Node, Involved Field, and Mantle Field Treatment for Pediatric Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2013, 87, S599-S600.	0.8	0
108	Impact of Treatment Margins and Treatment Technique in Hippocampal Sparing Radiation Therapy for Pediatric Medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2013, 87, S595.	0.8	3

#	Article	IF	CITATIONS
109	Involved Node Radiation Therapy: An Effective Alternative in Early-Stage Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1057-1065.	0.8	68
110	The effect on esophagus after different radiotherapy techniques for early stage Hodgkin's lymphoma. Acta Oncológica, 2013, 52, 1559-1565.	1.8	27
111	Reduced lung dose and improved inspiration level reproducibility in visually guided DIBH compared to audio coached EIG radiotherapy for breast cancer patients. Acta Oncológica, 2013, 52, 1458-1463.	1.8	41
112	Failure-probability driven dose painting. Medical Physics, 2013, 40, 081717.	3.0	26
113	Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Annals of Oncology, 2013, 24, 2113-2118.	1.2	121
114	SU-E-T-167: QA of Dose-Painting Plans: Risk of Overdosage in the High-Dose Regions?. Medical Physics, 2013, 40, 242-242.	3.0	0
115	Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastoma. Neuro-Oncology, 2012, 14, 882-889.	1.2	69
116	Risk of Developing Cardiovascular Disease After InvolvedÂNode Radiotherapy Versus Mantle Field for Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1232-1237.	0.8	91
117	A method to adjust radiation dose–response relationships for clinical risk factors. Radiotherapy and Oncology, 2012, 102, 352-354.	0.6	9
118	Deep-inspiration Breath Hold Versus Intensity Modulated Radiation Therapy in Minimizing Late Side Effects in Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2012, 84, S71-S72.	0.8	0
119	A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncológica, 2012, 51, 975-983.	1.8	190
120	Quantitative Cell-Free DNA, <i>KRAS</i> , and <i>BRAF</i> Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan. Clinical Cancer Research, 2012, 18, 1177-1185.	7.0	244
121	Life years lost—comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale. Cancer, 2012, 118, 5432-5440.	4.1	61
122	Methods for estimating the site of origin of locoregional recurrence in head and neck squamous cell carcinoma. Strahlentherapie Und Onkologie, 2012, 188, 671-676.	2.0	34
123	Photon and proton therapy planning comparison for malignant glioma based on CT, FDG-PET, DTI-MRI and fiber tracking. Acta Oncológica, 2011, 50, 777-783.	1.8	38
124	Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. Acta Oncológica, 2011, 50, 806-816.	1.8	132
125	Estimated radiation pneumonitis risk after photon versus proton therapy alone or combined with chemotherapy for lung cancer. Acta OncolÅ <sup>3</sup> gica, 2011, 50, 772-776.	1.8	25
126	Estimating Life Years Lost to Quantify the Potential Benefit for Pediatric Patients of Advanced Photon or Proton Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, S665.	0.8	0

#	Article	IF	CITATIONS
127	Comparison of Methods to Analyze Pattern of Failure in Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, S540.	0.8	0
128	Comparison of Cardiac Doses after Involved Node Radiotherapy and Mantle Field Treatment for Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, S19.	0.8	0
129	Meta-analysis of the α/β-ratio for Prostate Cancer in the Presence of an Overall Time Factor: Bad News, Good News or No News?. International Journal of Radiation Oncology Biology Physics, 2011, 81, S404.	0.8	1
130	Risk factors for radiation-induced hypothyroidism. Cancer, 2011, 117, 5250-5260.	4.1	87
131	Artifacts in Conventional Computed Tomography (CT) and Free Breathing Four-Dimensional CT Induce Uncertainty in Gross Tumor Volume Determination. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1573-1580.	0.8	53
132	In Response to Dr. Williams. International Journal of Radiation Oncology Biology Physics, 2011, 80, 639-640.	0.8	2
133	A Prospective Phase III Randomized Trial of Hypofractionation Versus Conventional Fractionation in Patients With High-Risk Prostate Cancer: In Regard to Arcangeli C, et al. (Int J Radiat Oncol Biol Phys) Tj ETQq1 1	0.084314	rgBT /Overlo
134	Intensity-Modulated Radiotherapy Might Increase Pneumonitis Risk Relative to Three-Dimensional Conformal Radiotherapy in Patients Receiving Combined Chemotherapy and Radiotherapy: A Modeling Study of Dose Dumping. International Journal of Radiation Oncology Biology Physics, 2011, 80, 893-899.	0.8	32
135	A closer look at RapidArc® radiosurgery plans using very small fields. Physics in Medicine and Biology, 2011, 56, 1853-1863.	3.0	26
136	A New Method for Synthesizing Radiation Dose–Response Data From Multiple Trials Applied to Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1066-1071.	0.8	37
137	Radiation Dose–Volume Effects in the Lung. International Journal of Radiation Oncology Biology Physics, 2010, 76, S70-S76.	0.8	878
138	Methodologies for localizing loco-regional hypopharyngeal carcinoma recurrences in relation to FDC-PET positive and clinical radiation therapy target volumes. Acta Oncológica, 2010, 49, 984-990.	1.8	12
139	Hypofractionation does not increase radiation pneumonitis risk with modern conformal radiation delivery techniques. Acta Oncológica, 2010, 49, 1052-1057.	1.8	26
140	Absorption measurements on a new cone beam CT and IMRT compatible tabletop for use in external radiotherapy. Physics in Medicine and Biology, 2009, 54, N319-N328.	3.0	6
141	SU-FF-T-519: Potential for Increased Pneumonitis Risk with IMRT as Compared to 3D-CRT for Patients Receiving Adjuvant Chemotherapy: A Radiobiological Modeling Study. Medical Physics, 2009, 36, 2643-2643.	3.0	0
142	Probabilistic state preparation of a single molecular ion by projection measurement. Journal of Physics B: Atomic, Molecular and Optical Physics, 2006, 39, S1259-S1265.	1.5	25
143	Rotational cooling of molecular ions through laser-induced coupling to the collective modes of a two-ion Coulomb crystal. Journal of Physics B: Atomic, Molecular and Optical Physics, 2006, 39, S1267-S1280.	1.5	17
144	Rotational cooling of molecules using lamps. Journal of Physics B: Atomic, Molecular and Optical Physics, 2004, 37, 4571-4574.	1.5	14

#	Article	IF	CITATIONS
145	Rotational cooling of heteronuclear molecular ions withΣ1,Σ2,Σ3, andÎ2electronic ground states. Physical Review A, 2004, 70, .	2.5	40
146	Photo-dissociation of Cold MgH \$mathsf{^ + }\$ ions. European Physical Journal D, 2004, 31, 403-408.	1.3	17
147	News on 12C from β-decay studies. Nuclear Physics A, 2004, 738, 59-65.	1.5	11
148	New information on 12C states from the decays of 12N and 12B. Nuclear Physics A, 2003, 718, 541-543.	1.5	8
149	Dynamics of a single Rydberg shell in time dependent external fields*. Journal of Physics B: Atomic, Molecular and Optical Physics, 2002, 35, 401-419.	1.5	12
150	Correlated emission of three α-particles in the β-decay of 12N. European Physical Journal A, 2002, 15, 135-138.	2.5	14